Biohaven Ltd. (NYSE:BHVN) Position Boosted by Intech Investment Management LLC

Intech Investment Management LLC lifted its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 202.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,165 shares of the company’s stock after purchasing an additional 22,858 shares during the period. Intech Investment Management LLC’s holdings in Biohaven were worth $1,276,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Citigroup Inc. lifted its position in shares of Biohaven by 125.8% during the third quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock worth $5,992,000 after purchasing an additional 66,801 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Biohaven by 9.1% during the fourth quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company’s stock worth $11,021,000 after purchasing an additional 24,703 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Biohaven during the third quarter worth about $1,339,000. JPMorgan Chase & Co. lifted its position in shares of Biohaven by 85.4% during the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after purchasing an additional 372,737 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in Biohaven by 278.5% in the third quarter. XTX Topco Ltd now owns 32,510 shares of the company’s stock worth $1,625,000 after acquiring an additional 23,921 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

BHVN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Biohaven in a report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 target price on the stock. JPMorgan Chase & Co. cut their target price on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley cut their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $63.15.

Insider Activity at Biohaven

In related news, Director John W. Childs acquired 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 16.00% of the company’s stock.

Biohaven Price Performance

NYSE BHVN opened at $28.61 on Friday. Biohaven Ltd. has a 12 month low of $26.80 and a 12 month high of $59.53. The firm has a market capitalization of $2.92 billion, a PE ratio of -3.06 and a beta of 1.27. The company’s 50 day simple moving average is $35.89 and its 200 day simple moving average is $41.60.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). Sell-side analysts anticipate that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.